InDevR

InDevR is a specialized provider of multiplexed immunoassay technology focused on the vaccine sector. Its VaxArray Platform uses microarray technology to enable high-throughput, simultaneous analysis of multiple vaccine components, significantly speeding up development and quality control processes compared to traditional methods like ELISA. The company serves vaccine developers and manufacturers by offering standardized, regulatory-compliant tools and custom services, aiming to reduce assay development time from months to days. In 2026, InDevR was acquired by SSI Diagnostica Group, providing it with expanded commercial reach and resources.

VaxArray Platform: A benchtop microarray-based system for multiplexed immunoassays. It enables simultaneous analysis of dozens of vaccine components (proteins, antibodies, polysaccharides, mRNA) in a single run, providing automated results in under 2 hours. The platform supports off-the-shelf assay kits and custom assay development.

InDevR competes with other multiplex immunoassay providers like Luminex (DiaSorin) and Meso Scale Discovery (MSD), as well as traditional single-plex methods (ELISA, HPLC). Its differentiation lies in its specific focus on vaccine analytics, benchtop format, and custom design services for novel vaccine modalities.